{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:25:07Z","timestamp":1793413507392,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00108-022-01326-8","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T08:05:47Z","timestamp":1649750747000},"page":"484-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prophylaktisches und therapeutisches Management erh\u00f6hter Infektionsanf\u00e4lligkeit bei Immundefekten","Prophylactic and therapeutic management of increased susceptibility to infection in patients with immunodeficiency"],"prefix":"10.1007","volume":"63","author":[{"given":"Leif G.","family":"Hanitsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"1326_CR1","unstructured":"Famand\u00a0S et\u00a0al https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/112-001l_S2k_Primaere_Immundefekte_PID_2017-11_verlaengert.pdf. Zugegriffen: 24.03.2022"},{"key":"1326_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00758-x","author":"A Bousfiha","year":"2020","unstructured":"Bousfiha\u00a0A, Jeddane\u00a0L, Picard\u00a0C, Al-Herz\u00a0W, Ailal\u00a0F, Chatila\u00a0T et al (2020) Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J\u00a0Clin Immunol. https:\/\/doi.org\/10.1007\/s10875-020-00758-x","journal-title":"J Clin Immunol"},{"key":"1326_CR3","unstructured":"Hanitsch LG et\u00a0al https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/189-001l_S3_Therapie-primaerer-Antikoerpermangelerkrankungen-2019-05_01.pdf. Zugegriffen: 24.03.2022"},{"issue":"2 Suppl 2","key":"1326_CR4","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1016\/j.jaci.2009.08.040","volume":"125","author":"J Chinen","year":"2010","unstructured":"Chinen\u00a0J, Shearer\u00a0WT (2010) Secondary immunodeficiencies, including HIV infection. J\u00a0Allergy Clin Immunol 125(2 Suppl 2):S195\u2013S203","journal-title":"J Allergy Clin Immunol"},{"key":"1326_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel\u00a0SY, Carbone\u00a0J, Jolles\u00a0S (2019) The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol 10:33","journal-title":"Front Immunol"},{"issue":"Suppl 2","key":"1326_CR6","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","volume":"24","author":"M Mikulska","year":"2018","unstructured":"Mikulska\u00a0M, Lanini\u00a0S, Gudiol\u00a0C, Drgona\u00a0L, Ippolito\u00a0G, Fern\u00e1ndez-Ruiz\u00a0M et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 24(Suppl 2):S71\u2013s82","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"1326_CR7","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"G Redelman-Sidi","year":"2018","unstructured":"Redelman-Sidi\u00a0G, Michielin\u00a0O, Cervera\u00a0C, Ribi\u00a0C, Aguado\u00a0JM, Fern\u00e1ndez-Ruiz\u00a0M et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect 24(Suppl 2):S95\u2013S107","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"1326_CR8","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","volume":"24","author":"M Reinwald","year":"2018","unstructured":"Reinwald\u00a0M, Silva\u00a0JT, Mueller\u00a0NJ, Fort\u00fan\u00a0J, Garzoni\u00a0C, de Fijter\u00a0JW et\u00a0al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect 24(Suppl 2):S53\u2013S70","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"1326_CR9","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.cmi.2018.01.029","volume":"24","author":"M Fern\u00e1ndez-Ruiz","year":"2018","unstructured":"Fern\u00e1ndez-Ruiz\u00a0M, Meije\u00a0Y, Manuel\u00a0O, Akan\u00a0H, Carratal\u00e0\u00a0J, Aguado\u00a0JM et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clin Microbiol Infect 24(Suppl 2):S2\u2013S9","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"1326_CR10","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","volume":"24","author":"JW Baddley","year":"2018","unstructured":"Baddley\u00a0JW, Cantini\u00a0F, Goletti\u00a0D, G\u00f3mez-Reino\u00a0JJ, Mylonakis\u00a0E, San-Juan\u00a0R et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor\u2011\u03b1 agents). Clin Microbiol Infect 24(Suppl 2):S10\u2013S20","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"1326_CR11","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop\u00a0KL, Mariette\u00a0X, Silva\u00a0JT, Benamu\u00a0E, Calabrese\u00a0LH, Dumusc\u00a0A et\u00a0al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24(Suppl 2):S21\u2013S40","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"1326_CR12","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1002\/art.21386","volume":"52","author":"J Listing","year":"2005","unstructured":"Listing\u00a0J, Strangfeld\u00a0A, Kary\u00a0S, Rau\u00a0R, von Hinueber\u00a0U, Stoyanova-Scholz\u00a0M et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52(11):3403\u20133401","journal-title":"Arthritis Rheum"},{"key":"1326_CR13","unstructured":"Schaberg T et\u00a0al https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/020-019l_S2k_Tuberkulose_im_Erwachsenenalter_2017-11-abgelaufen_01.pdf. Zugegriffen: 24.03.2022"},{"key":"1326_CR14","unstructured":"Cornberg M et\u00a0al https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/021-011l_S3_Prophylaxe-Diagnostik-Therapie-der-Hepatitis-B-Virusinfektion_2021-07.pdf. Zugegriffen: 24.03.2022"},{"key":"1326_CR15","unstructured":"Hemmer B et\u00a0al https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/030-050LGl_S2e_Diagnose-Therapie-Multiplen-Sklerose-Neuromyelitis-Optica-Spektrum-MOG-IgG-assoziierte_Erkrankungen_2021-05_1.pdf. Zugegriffen: 24.03.2022"},{"key":"1326_CR16","volume-title":"National Institute for Health and Care Excellence: Clinical Guidelines. Tuberculosis: Prevention, Diagnosis, Management and Service Organisation","author":"T Internal Clinical Guidelines","year":"2016","unstructured":"Internal Clinical Guidelines\u00a0T (2016) National Institute for Health and Care Excellence: Clinical Guidelines. Tuberculosis: Prevention, Diagnosis, Management and Service Organisation. National Institute for Health and Care Excellence, London"},{"issue":"3","key":"1326_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s00103-019-02897-y","volume":"62","author":"S Ehl","year":"2019","unstructured":"Ehl\u00a0S, Bogdan\u00a0C, Niehues\u00a0T, Burchard\u00a0G, Baumann\u00a0U, Hecht\u00a0J et\u00a0al (2019) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62(3):378","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"4","key":"1326_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","volume":"62","author":"N Wagner","year":"2019","unstructured":"Wagner\u00a0N, Assmus\u00a0F, Arendt\u00a0G, Baum\u00a0E, Baumann\u00a0U, Bogdan\u00a0C et\u00a0al (2019) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62(4):494\u2013515","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"10","key":"1326_CR19","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos\u00a0E, Kleber\u00a0M, Engelhardt\u00a0M, Zweegman\u00a0S, Gay\u00a0F, Kastritis\u00a0E et al (2015) European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100(10):1254\u20131266","journal-title":"Haematologica"},{"issue":"5","key":"1326_CR20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12067","volume":"159","author":"D Oscier","year":"2012","unstructured":"Oscier\u00a0D, Dearden\u00a0C, Eren\u00a0E, Fegan\u00a0C, Follows\u00a0G, Hillmen\u00a0P et\u00a0al (2012) Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol 159(5):541\u2013564","journal-title":"Br J Haematol"},{"key":"1326_CR21","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig_en-1.pdf. Zugegriffen: 24.03.2022"},{"issue":"1","key":"1326_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange\u00a0JS, Grossman\u00a0WJ, Navickis\u00a0RJ, Wilkes\u00a0MM (2010) Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 137(1):21\u201330","journal-title":"Clin Immunol"},{"issue":"5","key":"1326_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10875-012-9671-6","volume":"32","author":"LJ Maarschalk-Ellerbroek","year":"2012","unstructured":"Maarschalk-Ellerbroek\u00a0LJ, Hoepelman\u00a0AI, van Montfrans\u00a0JM, Ellerbroek\u00a0PM (2012) The spectrum of disease manifestations in patients with common variable immunodeficiency disorders and partial antibody deficiency in a\u00a0university hospital. J\u00a0Clin Immunol 32(5):907\u2013921","journal-title":"J Clin Immunol"},{"issue":"3","key":"1326_CR24","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino\u00a0E, Goeminne\u00a0PC, McDonnell\u00a0MJ, Aliberti\u00a0S, Marshall\u00a0SE, Loebinger\u00a0MR et\u00a0al (2017) European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir\u00a0J 50(3):1700629","journal-title":"Eur Respir J"},{"issue":"2","key":"1326_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jaci.2019.01.051","volume":"144","author":"C Milito","year":"2019","unstructured":"Milito\u00a0C, Pulvirenti\u00a0F, Cinetto\u00a0F, Lougaris\u00a0V, Soresina\u00a0A, Pecoraro\u00a0A et al (2019) Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies. J\u00a0Allergy Clin Immunol 144(2):584\u2013593.e7","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1326_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s10875-017-0469-4","volume":"38","author":"JDM Edgar","year":"2018","unstructured":"Edgar\u00a0JDM, Richter\u00a0AG, Huissoon\u00a0AP, Kumararatne\u00a0DS, Baxendale\u00a0HE, Bethune\u00a0CA et al (2018) Prescribing immunoglobulin replacement therapy for patients with non-classical and secondary antibody deficiency: an analysis of the practice of clinical immunologists in the UK and republic of ireland. J\u00a0Clin Immunol 38(2):204\u2013213","journal-title":"J Clin Immunol"},{"issue":"3","key":"1326_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","volume":"34","author":"F Dhalla","year":"2014","unstructured":"Dhalla\u00a0F, Lucas\u00a0M, Schuh\u00a0A, Bhole\u00a0M, Jain\u00a0R, Patel\u00a0SY et\u00a0al (2014) Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? J\u00a0Clin Immunol 34(3):277\u2013282","journal-title":"J Clin Immunol"},{"issue":"8","key":"1326_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1034\/j.1398-9995.2003.00219.x","volume":"58","author":"B Niggemann","year":"2003","unstructured":"Niggemann\u00a0B, Gr\u00fcber\u00a0C (2003) Side-effects of complementary and alternative medicine. Allergy 58(8):707\u2013716","journal-title":"Allergy"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01326-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01326-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01326-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:32:51Z","timestamp":1726965171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01326-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1326"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01326-8","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"30 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.G.\u00a0Hanitsch gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}